Schwartzberg Gil 4

4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Dec 7, 2020

Form 4

Period: 2020-11-30

10% Owner

Transactions

Purchase
Common Stock
2020-11-30$4.75/sh+105,264$500,004→ 247,775 total
Purchase
Warrant to Purchase Common Stock
2020-11-30$4.75/sh+105,264$500,004→ 105,264 total
Exercise: $5.70From: 2020-11-30Exp: 2025-11-30→ Common (105,264 underlying)

Holdings

Common Stock
(indirect: By Trust)
16,667
Common Stock
(indirect: By Trust)
16,667
Options to Purchase Common Stock
(indirect: By Trust)
Exercise: $3.00From: 2015-01-28Exp: 2024-01-28→ Common (291,667 underlying)
291,667
Warrant to Purchase Common Stock
(indirect: By Trust)
Exercise: $6.00From: 2018-12-07Exp: 2022-11-30→ Common (83,333 underlying)
83,333
Common Stock
(indirect: By Trust)
375,926
Warrant to Purchase Common Stock
(indirect: By Trust)
Exercise: $6.00From: 2018-12-07Exp: 2022-11-30→ Common (83,333 underlying)
83,333
Options to Purchase Common Stock
Exercise: $3.00From: 2015-01-28Exp: 2024-01-28→ Common (83,333 underlying)
83,333
Common Stock
(indirect: By Trust)
16,667
Common Stock
(indirect: By Trust)
186,667
Common Stock
(indirect: By Trust)
191,667
Common Stock
(indirect: By Trust)
33,333
Common Stock
(indirect: By Continuum Partners, L.P.)
106,352
Common Stock
(indirect: By Trust)
16,667

Footnotes (1)

[F1]The reporting person acquired 105,264 Units, each Unit consisting of one share of Common Stock and a five year warrant at an exercise price of $5.70 per share. The purchase price for a Unit was $4.75 per Unit.

Documents

1 file